Skip to content
Menu

Pliant Therapeutics, Inc. PLRX

Full chart Compare
Set alert

Price alert · PLRX

All alert types
0.60 USD -0.02 (-4.02%)

Regular-session close

0.60 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

0.5719 Day range 0.6139
0.5951 52-week range 1.61
YTD
-51.22%
1 year
-61.85%

5D -0.1200 (-16.22%)

0.60000.65000.70000.7500FriMonTueWedThu0.6200
Market cap
36.89M
EPS (ttm)
-1.46
Shares out
60.85M
Forward P/E
-3.32
YTD return
-51.22%
1-year return
-61.85%
50-day average
14.08
200-day average
13.14
Volume
933.40K
Avg volume
402.23K
Open
0.6001
Previous close
0.62
Day's range
0.5719 – 0.6139
52-week range
0.5951 – 1.61
Beta
1.09
Price target
40.18 (+6652.1%)

Key statistics

Enterprise value
459.58M
Price / book
2.35
Free cash flow
-84.08M
Total cash
404.51M
Total debt
60.21M
Return on equity
-47.52%
Short % of float
12.16%

Fundamental scorecard

5 of 25 checks passed on PLRX’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PLRX Revenue — quarterly 0
PLRX Net income — quarterly -24.38M
PLRX EPS — quarterly -0.39

Earnings

PLRX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.99-0.95+0.04+4.04%
Aug 7, 2024Jun 1, 2024-0.85-0.92-0.07-8.24%
Aug 7, 2024Jun 1, 2024-0.85———
May 6, 2024Mar 1, 2024-0.76-0.78-0.02-2.63%
May 6, 2024Mar 1, 2024-0.76———
Feb 27, 2024Dec 1, 20230.00———

Upgrades / downgrades

PLRX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 8, 2024HC Wainwright & Co.reitBuyBuy
Sep 13, 2024HC Wainwright & Co.reitBuyBuy
Aug 12, 2024HC Wainwright & Co.mainBuyBuy
Aug 8, 2024Cantor Fitzgeraldreit—Overweight
Aug 8, 2024OppenheimermainOutperformOutperform
Aug 8, 2024NeedhamreitBuyBuy

About Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
pliantrx.com

News

Your note

Sign in to keep a note on PLRX — it syncs with the Stock Master app.

Insider holders

PLRX insider holders
InsiderRelationLatest transactionDateShares held
CHEUNG LILYOfficerStock Award(Grant)Jan 22, 202426,795
COULIE BERNARD JChief Executive OfficerSaleJul 9, 2024892,253
CUMMINGS KEITH LAMONTChief Financial OfficerSaleJul 9, 2024282,115
HULL JOHANNES P.OfficerSaleJul 9, 2024259,285
LEFEBVRE ERICOfficerSaleJul 9, 2024213,052
OUIMETTE MICHAELGeneral CounselSaleJul 9, 202494,044

Institution ownership

PLRX institution ownership
Holder% heldSharesValueReported
Deep Track Capital, Lp9.81%5,972,25779.67MSep 29, 2024
Blackrock Inc.8.58%5,218,96569.62MSep 29, 2024
Price (T.Rowe) Associates Inc7.94%4,834,81364.50MSep 29, 2024
FMR, LLC6.41%3,899,48152.02MSep 29, 2024
Vanguard Group Inc5.80%3,526,51447.04MSep 29, 2024
Redmile Group, LLC5.25%3,197,49142.65MSep 29, 2024

Fund ownership

PLRX fund ownership
Holder% heldSharesValueReported
Price (T.Rowe) New Horizons Fund3.97%2,414,41332.21MSep 29, 2024
Vanguard Total Stock Market Index Fund3.34%2,030,49627.09MSep 29, 2024
iShares Russell 2000 ETF2.40%1,462,59219.51MOct 30, 2024
Fidelity Growth Company Fund2.18%1,324,09617.66MOct 30, 2024
Vanguard Extended Market Index Fund1.44%873,60611.65MSep 29, 2024
Fidelity Small Cap Index Fund0.95%579,9147.74MAug 30, 2024